Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prostrakan grants Tostran licence to Bayer Schering

This article was originally published in Scrip

Executive Summary

ProStrakanhas granted an exclusive licence to Bayer Schering Pharmato develop and commercialise Tostran (2% testosterone gel) in 65 countries. Bayer Schering will pay ProStrakan an undisclosed amount and milestones upon meeting certain approvals and sales targets. ProStrakan will supply the testosterone replacement therapy for hypogonadal men to Bayer Schering in Canada, Latin America, the Middle East, Africa, and the Asia-Pacific region. ProStrakan currently markets the product in Europe under the brand names Tostran, Tostrex and Itnogen. In the US, where Tostran is to be marketed as Fortigel, the company remained on course to re-submit its NDA for the product to the FDAby the end of the year, ProStrakan said.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts